2026年4月30日 / 美国东部时间下午5:59 / 哥伦比亚广播公司新闻
作者：梅根·塞鲁洛
梅根·塞鲁洛是哥伦比亚广播公司财经频道驻纽约记者，报道小企业、职场、医疗、消费者支出和个人理财话题。她经常亮相哥伦比亚广播公司24小时新闻频道解读其报道内容。
查看完整简介
糖果巨头好时公司正从一个意想不到的消费群体那里获得销量提振：GLP-1减肥药使用者。
好时首席执行官柯克·坦纳在周四的公司第一季度财报电话会议上表示，尽管食欲抑制剂正促使消费者减少热门零食的食用量，但这类药物同时也提振了口气清新产品的需求。
坦纳表示，公司“目睹了口香糖和薄荷糖产品的强劲需求，因为该品类受益于功能性零食的利好趋势，其中包括GLP-1药物的普及”。他指出，公司旗下的破冰者薄荷糖和口香糖品牌本季度销售额增长了8%。
一种可能的解释是：据医疗专业人士介绍，除了缩小腰围，奥司匹德和韦戈维这类药物有时会产生口臭的副作用。
“奥司匹德口臭指的是打嗝时出现的鱼腥味或口臭，”内科医生尼哈·拉拉尼告诉医疗信息提供商健康线网站。
GLP-1药物生产商并未将口臭（也称为口腔异味）列为这类药物的副作用。医生同时提醒称，这并非临床确诊病症，且药物对患者口腔卫生的影响仍在研究中。
在一项临床试验中，奥司匹德和韦戈维的生产商诺和诺德发现，约9%服用GLP-1药物的受试者报告出现“嗳气”，也就是打嗝。超过40%的受试者报告出现恶心，近25%的受试者报告呕吐为药物副作用。
阿尔兰·谢特编辑
“Ozempic breath” is boosting Hershey’s sales of mints and gum
April 30, 2026 / 5:59 PM EDT / CBS News
By Megan Cerullo
Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to discuss her reporting.
Read Full Bio
Candy giant Hershey is getting a sales boost from an unexpected consumer segment: users of GLP-1 weight-loss drugs.
Hershey CEO Kirk Tanner said in the company’s first-quarter earnings call on Thursday that while appetite suppressants are leading customers to consume smaller portions of popular snacks, the drugs are also boosting demand for breath fresheners.
The company has “seen strong demand for gum and mint products as the category benefits from functional snacking tailwinds, including GLP-1 adoption,” Tanner said. He noted that sales for the company’s Ice Breakers mint and gum brand increased 8% over the quarter.
One possible explanation: Along with slimming waistlines, drugs like Ozempic and Wegovy sometimes produce the side effect of bad breath, according to medical professionals.
“Ozempic breath refers to a fishy smell in burps or bad breath,” Dr. Neha Lalani told medical information provider Healthline.
GLP-1 makers don’t include bad breath, also known as halitosis, as a side effect of the drugs. Doctors also caution that it’s not a clinical diagnosis and that the drugs’ effects on patients’ oral hygiene are being studied.
In one clinical trial, the maker of Ozempic and Wegovy, Novo Nordisk, found that roughly 9% of people taking GLP-1 medications reported “eructation,” better known as burping. More than 40% reported nausea, and almost 25% reported vomiting as a side effect of the drugs.
Edited by Alain Sherter
发表回复